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ABSTRACT 
Altered synaptic structure and function is a major hallmark of Fragile X Syndrome (FXS), Autism 
Spectrum Disorders (ASDs) and other intellectual disabilities (IDs), which are therefore 
classified as synaptopathies. FXS and ASDs, while clinically and genetically distinct, share 
significant comorbidity, suggesting that there may be a common molecular and/or cellular basis, 
presumably at the synapse. In this article we review brain architecture and synaptic pathways 
that are dysregulated in FXS and ASDs, including spine architecture, signaling in synaptic 
plasticity, local protein synthesis, (m)RNA modifications and degradation. mRNA repression is 
a powerful mechanism for the regulation of synaptic structure and efficacy. We infer that there 
is no single pathway that explains most of the etiology and discuss new findings and the 
implications for future work directed at improving our understanding of the pathogenesis of FXS 
and related ASDs and the design of therapeutic strategies to ameliorate these disorders.  
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INTRODUCTION  
ASDs and FXS: Causes and Clinical Features 
Approximately 1%–3% of the general population is affected by intellectual disabilities 
(IDs). IDs are neurodevelopmental disorders defined by significant limitations in intellectual 
functioning and adaptive behaviors and often exhibit comorbidity with autism (Mefford et al., 
2012). ASDs are characterized by high phenotypic heterogeneity, comprising deficits in social 
interaction and communication, as well as repetitive and stereotyped behaviors (Bhat et al., 
2014; Volkmar and McPartland, 2014). ASDs have a strong and complex genetic component 
with multiple familial inheritance patterns and are estimated to be linked to mutations in as 
many as 1000 genes (see SFARI database). Over the past decade, genome-wide association 
studies have enabled rapid progress in the identification of risk genes for ASDs (Ramaswami 
and Geschwind, 2018).  
In addition to the genetic factors, environmental and/or immune factors contribute to 
the risk of autism during in early life (Waye and Cheng, 2018). The interaction of environmental 
exposures with an individual genetic background and particular susceptibility manifests 
differently in each case, leading to heterogeneous phenotypes and varied comorbid symptoms 
within the disorder. Among the environmental factors to consider are prenatal infections 
(maternal immune activation), maternal diabetes, zinc deficiency, prenatal and perinatal stress, 
and toxins (reviewed in Park et al., 2016). Several reports suggest that exposure to various 
toxicants including pesticides, polychlorinated biphenyls, and polybrominated diphenyl ethers 
(PBDEs), can have detrimental consequences on developmental processes. The negative 
effects could be exacerbated in genetically susceptible individuals (Mostafalou and Abdollahi, 
2017).  
Several genetic syndromes are known to have significant associations with autism 
(Borrie et al., 2017). Study of these autism-related syndromes, which are well-defined genetic 
disorders, has yielded major insights into ASDs. For example, Tuberous sclerosis complex (TSC) 
is an autosomal dominant genetic disorder characterized by the formation of hamartomas in 
different organs, including the brain, and it is caused by mutations in the TSC1 or TSC2 genes 
encoding hamartin and tuberin respectively. The TSC protein complex inhibits the mechanistic 
target of rapamycin (mTOR) signalling pathway (Henske et al., 2016; Jeste et al., 2016). Children 
and adolescents with TSC display epilepsy, cognitive disorders and around 30-40% autism 
(Curatolo et al., 2010). 
Another important example of syndromic autism is Fragile X Syndrome (FXS), the most 
prevalent neurodevelopmental disorder with a genetic origin characterized by a high incidence of 
autism. FXS, first described by Martin and Bell in 1943 has a prevalence of approximately 1 in 
4000 males and 1 in 8000 females. It is an X-linked condition caused, in the majority of cases, by 
an unstable CGG trinucleotide repeat expansion (200 or more) in the 5’-untranslated region 
(UTR) of the fragile X mental retardation 1 (FMR1) gene (Bagni et al., 2012), leading to its 
hypermethylation and transcriptional silencing (Bagni et al., 2012; Berry-Kravis et al., 2018; 
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Nelson et al., 2013). Over the past years rare FMR1 gene mutations, affecting the coding or non-
coding region of the gene and causing FXS, have also been reported (Sitzmann et al., 2018). 
Fragile X mental retardation protein (FMRP), the product of the FMR1 gene, is an RNA 
binding protein that tightly controls the localization, stability and translation of a large array of RNAs 
critical to neuronal development, synaptic plasticity and dendritic spine architecture (for recent 
review, see Banerjee et al., 2018; Braat and Kooy, 2015; Contractor et al., 2015; Huber et al., 
2015; Richter et al., 2015). The behavioral phenotype of children with FXS can vary greatly 
among individuals, although there are several “core” behaviors seen in the youngest patients. 
Avoidant eye gaze, Attention Deficit Hyperactivity Disorder (ADHD), hand flapping, repetitive 
behaviors, reduced social interactions, anxiety and speech perseverations have been reported 
in 60 to 90% of individuals with FXS (Bagni et al., 2012; Roberts et al., 2018). On the more 
extreme end, some patients with FXS and autism are completely nonverbal, exhibit aggressive 
or self-injurious, repetitive and/or stereotyped behaviors, and severe intellectual disability. 
Around 40% to 60% of male and 20% of female patients with FXS meet the criteria for ASDs 
(Kaufmann et al., 2017). ASDs seem to be a distinctive subphenotype in FXS characterized by 
deficits in complex social interaction, with similarities to ASDs in the general population 
(Hernandez et al., 2009). Individuals with FXS and ASDs also have a lower IQ and more 
stereotyped and aggressive behaviors, impaired expressive syntax, hyperactivity, emotional 
lability, attentional deficits, resistance to change, seizures, sleep disorders, hypersensitivity to 
sensory stimuli and autonomic dysfunction (Bailey et al., 1998; Hatton et al., 1999; Kaufmann 
et al., 2017; McDuffie et al., 2010; Thurman et al., 2015). Of note, the observed impaired 
expressive syntax may contribute to atypical social behaviors and thereby, ASD symptoms 
(Abbeduto et al., 2018). 
 
FXS and ASDs: Common features in genetic makeup and brain circuitry. 
Our brains undergo remarkable changes throughout infancy, childhood, and 
adolescence. Processes including myelination and synaptogenesis (Remer et al., 2017) occur 
across the first years of life, and brain remodeling continues into young adulthood. 
Approximately one-third of the human genes are expressed primarily in the brain and during 
brain development (Douet et al., 2014). Genes that influence developmental and age-specific 
brain trajectories play an important role in several critical events in neurodevelopmental 
disorders such as ASDs (reviewed in Parikshak et al., 2015). The identification of large 
biological networks of genes affected by rare de novo copy number variants in autism revealed 
that the genes forming networks are primarily related to synapse development, axon targeting 
and cytoskeleton organization (De Rubeis et al., 2014; Gilman et al., 2011), processes that 
ultimately shape our brain. 
Mutations in many genes linked to ASDs and related disorders affect the 
excitatory/inhibitory balance in neurons. Perturbations in synaptic physiology and neuronal 
circuitry have recently been reviewed (e.g., Contractor et al., 2015), and will therefore be 
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mentioned only briefly here. Hyperexcitability of excitatory neurons is a recurring topic in FXS 
(see below). In addition, there is evidence for weakened inhibitory drive. Notable examples are 
decreased GABAA receptor expression in the hippocampus of FXS patients and Fmr1 KO mice 
(Gantois et al., 2006; Gao et al., 2018; Kang et al., 2017), and a reduction in the frequency and 
amplitude of miniature and spontaneous IPSCs in the mature amygdala (Olmos-Serrano et al., 
2010). Moreover, development of the inhibitory network is delayed. In rodents, GABAA 
receptors switch on at postnatal day ~7 from primarily depolarizing (excitatory) to 
hyperpolarizing (inhibitory), largely due to a changing Cl- gradient (Cherubini et al., 2011). This 
switch is delayed in layer 4 neurons of the somatosensory cortex of Fmr1 KO mice (He et al., 
2014). Similarly, fast-spiking (FS) interneurons in layer IV of neocortex that lack FMRP remain 
excitatory throughout the critical period (up to P9, Nomura et al., 2017), with important 
consequences for synaptic and circuit properties in the mature cortex. Of note, an imbalance 
in the excitatory to inhibitory ratio (E/I) is a common theme in FXS and other ASDs (Nelson and 
Valakh, 2015). 
 
Brain structure and functional connectivity: lessons from Magnetic Resonance Imaging 
While in the past, studies in brain relied predominately upon gross anatomical measures of 
brain structure, morphology, and organization, more advanced non-invasive imaging 
techniques now offer the ability to characterize and quantify a range of functional and 
microstructural aspects of brain tissue that may be more closely related to fundamental 
neurodevelopmental processes (Khundrakpam et al., 2016; Lebel and Deoni, 2018). 
Specifically, MRI produces detailed three-dimensional anatomical images without the use of 
damaging radiation. In addition, sophisticated MRI imaging techniques yield invaluable 
information about brain connectivity. Resting-state functional MRI measures brain functional 
connectivity (FC). Diffusion tensor imaging (DTI) tractography, and especially its most important 
read-out, the fractional anisotropy (FA), is a measure of axonal integrity. While MRI techniques 
do not have the spatial and temporal resolution to arrive at the cellular level, they are very 
powerful because they are in vivo and non-invasive, with a high translational potentiality. Over 
the past years neuroimaging studies have linked genetics with brain development from infancy 
to young adulthood (Douet et al., 2014), providing complementary information to age-specific 
brain trajectories based on gene expression.  
Neuroimaging studies demonstrate that ASDs and other psychiatric disorders are 
correlated with diffuse alterations in large-scale functional and structural brain networks 
(Baribeau and Anagnostou, 2013). Likewise, suboptimal levels of FMRP in the developing brain 
appear to be detrimental for brain wiring (Dennis and Thompson, 2013). Imaging studies in 
humans with FXS (Swanson et al., 2018) and ASDs (Ha et al., 2015) reveal aberrant structure 
of multiple brain regions. Specifically, long-range FC is altered in ASD and FXS patients (Hall 
et al., 2013; Holsen et al., 2008; Yerys et al., 2017). Additionally, axonal integrity and 
connectivity as measured by DTI is also affected in patients with FXS who exhibit significantly 
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larger or smaller grey matter volume in the bilateral caudate nucleus and other regions relative 
to controls (Sandoval et al., 2018). The white matter in fronto-striatal pathways, as well as in 
parietal sensory-motor tracts, is also affected (Barnea-Goraly et al., 2003). In addition, 
microstructural defects as measured by reduction in FA of white matter tracts, predominantly 
in the corpus callosum, have been found in both FXS individuals and mouse models (Haberl et 
al., 2015; Swanson et al., 2018).  
MRI studies in Fmr1 KO mice identified reduced volume of certain brain areas 
(Ellegood et al., 2010). Ex-vivo DTI of FMR1 KO mice revealed a reduced diffusivity in the 
cortex of juvenile FXS mice suggesting structural changes in axonal fiber patterns and integrity, 
indicative of subtle changes in connectivity at early developmental stages (La Fata et al., 2014). 
In addition, in-vivo imaging of FXS mice show an anatomical hyperconnectivity phenotype in 
the primary visual cortex but a disproportional low connectivity with other neocortical regions 
(Haberl et al., 2015; Zerbi et al., 2018). These observations are consistent with findings in FXS 
human infants at the onset of the critical period, who exhibit an increased density of DTI-
reconstructed fibers relative to that of normal children (Haas et al., 2009; Swanson et al., 2018). 
Similarly, deletions and/or duplications in ASD-associated chromosomal regions, such 
as the 16p11.2 and the 15q11.2, also lead to abnormalities in brain FC and morphology. For 
instance, FC in the prefrontal cortex has been found to be impaired in humans and mice with 
the 16p11.2 deletion (Bertero et al., 2018). Patients with deletions and duplications in the 
16p11.2 chromosomal region also present global and regional differences in brain structure 
compared to controls (Blackmon et al., 2018; Martin-Brevet et al., 2018; Qureshi et al., 2014). 
In the 16p11.2 hemideletion mouse, there are pronounced sex-specific changes in males with 
increased FA in medial fiber tracts, especially in those proximal to the striatum, which correlate 
with gene expression patterns associated with neurite outgrowth and the the mitogen-activated 
protein kinase (MAPK) pathway (Kumar et al., 2018). Furthermore, patients with deletions and 
duplications in the 15q11.2 chromosomal region present abnormalities in white matter 
architecture and brain structure (Silva et al., 2018; Stefansson et al., 2014; Ulfarsson et al., 
2017; Vanlerberghe et al., 2015). Finally, genetic variations in the CNTNAP2 gene in humans 
have been associated with ASDs (Peñagarikano and Geschwind, 2012), and KO of this gene 
in mice leads to reduced FC and aberrant white matter morphology (Liska et al., 2018; Zerbi et 
al., 2018). In conclusion, there are consistent deficits detected by MRI in ASD patients and the 
respective mouse models. Of note, there is heterogeneity in the brain regions affected which 
might be helpful for patient stratification (Ellegood et al., 2010). 
 
 
 
 
Spine structure in humans and mice 
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The maturation and maintenance of the pre- and postsynaptic compartments depends 
upon the activation status of a synapse that defines its connection strength (Holtmaat and 
Svoboda, 2009). It is thought that defects in spines can give rise to impaired synaptic maturation 
and may contribute to cognitive deficits observed in individuals with this debilitating condition. Of 
note, more than 50% of the intellectual disability (ID) genes encode for proteins which are part of 
the pre- or post-synaptic compartments or implicated in synaptic functions by regulating synapse 
formation, synaptic actin cytoskeleton assembly or disassembly, or synaptic plasticity (Ropers and 
Hamel, 2005; Verpelli and Sala, 2012) and form the unifying synapse-based theory for cognitive 
and behavioural deficits.   
Human neuropathological and genetic findings on model systems suggest that FXS and 
ASDs may be conceptualized as diseases of the synapse because of the aberrant dendritic spine 
morphology and density (Bourgeron, 2015; Zoghbi and Bear, 2012). Golgi staining of postmortem 
brain of FXS-affected individuals revealed a deficit in the number, structure and morphology of the 
synapses. Specifically, FXS patients exhibit a higher density of dendritic spines on distal segments 
of apical and basal dendrites in the cingulate, temporal and visual cortex, with increased incidence 
of immature spine morphology and a decrease in mature morphologies. Both temporal and visual 
cortex exhibited significantly longer and fewer short dendritic spines than control subjects (Martínez-
Cerdeño, 2017). 
Increased spine density has been observed in brain tissues from humans with ASDs, 
whereas an increase in spine density on apical dendrites of pyramidal neurons in some, but not 
all, cortical brain areas was detected (Hutsler and Zhang, 2010). Furthermore, reduced 
developmental spine pruning in layer V pyramidal neurons in postmortem ASD temporal lobe 
has been shown to correlate with hyperactivated mammalian target of rapamycin (mTOR) and 
impaired autophagy (Tang et al., 2014). The mouse model for FXS also presents an 
overabundance of dendritic spines with an immature morphology (reviewed in He and Portera-
Cailliau, 2013), even though some studies report no detectable spine alteration in FXS. Thus, 
stimulated emission depletion microscopy (STED) detected only subtle differences in the Fmr1 
KO mice that are dependent on age and brain region (Wijetunge et al., 2014). It is possible that 
the apparent discrepancy is due to a difference in technique, region or developmental stages 
(reviewed in He and Portera-Cailliau, 2013). Mouse models of ASDs with specific genetic 
mutations such as the Cyfip1, Tsc2, Shank3 or Neuroligin-1 genes also present abnormalities 
in spine morphology and/or number (De Rubeis et al., 2013; Oguro-Ando et al., 2015; Pathania 
et al., 2014; Peca et al., 2011; Schnell et al., 2014; Varghese et al., 2017). 
 
 
Molecular Signaling 
Another aspect of convergence at the synapse is dysregulation of the mTOR and 
MAPK/extracellular signal–regulated kinase (ERK) signaling cascades. Molecules in these 
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pathways (Figure 1) such as Tuberous Sclerosis Complex 1 and 2 (TSC1 and TSC2), 
neurofibromatosis 1 (NF1), Phosphatase and Tensin homolog (PTEN), MAPK-interacting kinase 1 
and 2 (MNK1 and MNK2) and ERK1/2 are dysregulated in FXS, TSC1/2, Angelman syndrome, and 
Rett syndrome (Borrie et al., 2017; Huber et al., 2015; Mellios et al., 2018; Zoghbi and Bear, 2012). 
Mutations in TSC1/2, PTEN, MNK1 and MNK2 cause an imbalance in protein synthesis. Of 
note, the mTOR and MAPK pathways were recently found to be dysregulated in blood from patients 
with idiopathic ASDs and to possibly constitute a molecular signature for the severity of the disease 
(Rosina et al., 2019, Figure 1). These observations raise the possibility that dysregulation of mTOR 
and MAPK may be a unifying theme in individuals with FXS and a subset of ASDs (Abrahams and 
Geschwind, 2008; Subramanian et al., 2015). 
Activation of cell surface receptors such as NMDA-type glutamate receptors 
(NMDARs), metabotropic glutamate receptors (mGluRs) and TRK receptors activate the MAPK 
via ERK, and the mTOR pathway via the phosphoinositide-3 (PI3K) and AKT kinases. The 
ERK/MAPK pathway plays an important role in neural progenitor biogenesis, synaptic plasticity 
and consolidation of memory and its dysregulation is implicated in the pathophysiology of fragile 
X (Zoghbi and Bear, 2012). ERK/MAPK signaling is hyperactivated in brains of both FXS 
patients and Fmr1 KO mice (Sawicka et al., 2016; Wang et al., 2012). Interestingly, the 
cleavage product of the amyloid precursor protein (APP), the soluble APPα, is upregulated in 
Fmr1 KO mice, leading to elevated activation of ERK1/2 (Pasciuto et al., 2015). Furthermore, 
dysregulated dephosphorylation of ERK in response to mGluR1/5 stimulation was observed in 
Fmr1 KO cortical synaptoneurosomes (Kim et al., 2008). Intriguingly, the 16p11.2 locus deletion 
includes the MAPK3 gene and is associated with ASDs (Fasano and Brambilla, 2011). Mice 
harboring the 16p11.2 deletion show disruption of the MAPK pathway and behavioral defects. 
ERK pathway inhibition during development improves the molecular and behavioral defects 
observed in those mice, suggesting the MAPK pathway as a potential therapeutic approach for 
16p11.2 microdeletion syndrome (Pucilowska et al., 2018).  Of note, the MAPK and mTOR 
pathways converge on regulation of protein translation, which plays a crucial role in synaptic 
plasticity (see below). 
mTOR is a central regulator of cell growth, proliferation, cell cycle, ribosome 
biogenesis, autophagy, translation, and actin polymerization (Costa-Mattioli and Monteggia, 
2013; Laplante and Sabatini, 2012). Components of the mTOR cascade are present at 
synapses where they influence synaptic plasticity via regulation of local protein synthesis in 
dendrites and actin polymerization in spines (Huang et al., 2013; Tang et al., 2002). Whereas 
mTOR complex 1 (mTORC1) is a master regulator of cap-dependent translation (Darnell and 
Klann, 2013), mTORC2 is a central regulator of the actin cytoskeleton through its actions on 
the actin-depolymerizing factor cofilin (Costa-Mattioli and Monteggia, 2013; Laplante and 
Sabatini, 2012, see also below). Moreover, mTORC2 (but not mTORC1) has been shown to 
be critical to mGluR-LTD and related behaviors (Zhu et al., 2018).  
Fragile X mice exhibit over-activated mTORC1 signaling at hippocampal synapses, 
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which is causally related to an over-activation of p70 S6 kinase 1 (S6K1, Ronesi et al., 2012; 
Sharma et al., 2010). Moreover, crossing Fmr1 KO mice with mice lacking both alleles of the 
gene encoding S6K1 corrects signaling, spine morphology, and autism-relevant behaviors 
(Bhattacharya et al., 2016). Although dysregulation of mTORC1 has been documented in 
Fragile X humans (Hoeffer et al., 2012), mice (Sharma et al., 2010) and flies (Gross et al., 
2015), a role for mTORC2 is, as yet unclear. A recent finding that chronic treatment with 
rapamycin, which inhibits mTOR, had an adverse effects on sleep and social behavior in both 
control and Fmr1 KO mice (Saré et al., 2017) may simply reflect the not unexpected observation 
that not only too much, but also too little, mTOR activity is deleterious (Saré et al., 2017). 
Interestingly, mTOR dysregulation has also been observed in ASD patients with 15q11-13 
duplication, and in a mouse model overexpressing the Cyfip1, part of the 15q11-13 region 
(Oguro-Ando et al., 2015). 
 
Lipid signaling at FXS and ASD synapses 
The brain is particularly enriched in lipids and maintains a highly diverse lipid 
composition. Overwhelming evidence has identified key roles for signaling lipids in mediating 
membrane traffic and signal transduction at synapses. In particular phosphoinositides (PIPs) 
have important pre- and postsynaptic functions (Di Paolo and De Camilli, 2006) including the 
regulation of exo- and endocytosis of synaptic vesicles and postsynaptic receptors, 
conductance of ion channels, and signaling from activated neuroreceptors such as mGluRs 
and NMDARs to allow plastic regulation of synaptic function, which is widely believed to 
underlie cognition and behavior. Furthermore, mechanical deformation of the lipid bilayer is 
sufficient to modulate the gating properties of several channels (Phillips et al., 2009) suggesting 
that membrane lipid composition and organization of the spine is different from that of the 
dendritic shaft, from which these protrusions emerge (Dotti et al., 2014). 
In spite of the importance of lipid signaling for regulating synaptic function, its role in 
synaptopathies remains largely unexplored. Altered lipid signaling is associated with neuronal 
diseases. Emerging evidence implicates defective PIP metabolism in intellectual disabilities 
(IDs) and ASDs (Gross, 2017). Loss-of-function mutations in the acid sphingomyelinase (ASM) 
gene cause Niemann-Pick disease type A (NPA, Schiffmann, 1996), a rare disorder 
characterized by the accumulation of sphingomyelin (SM) in lysosomes and plasma membrane 
of neurons, which causes severe ID, premature aging and child death in early age due to the 
accumulation of sphingomyelin (SM) in lysosomes and plasma membrane of neurons. A 
contribution to the cause of the disease comes from impaired activity of the plasma membrane 
calcium ATPase which increases intracellular calcium and oxidative stress (Perez-Canamas et 
al., 2017).  
 
Therefore, defective lipid signaling seems to be a common theme in the synaptic and 
neurophysiological deficits underlying ID/ASD and related synaptopathies. In the case of FXS, 
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a retrospective study suggested that total cholesterol, low density lipoprotein and high density 
lipoprotein levels are lower in males with FXS than in the general population (Berry-Kravis et 
al., 2015). In the absence of FMRP, diacylglycerol (DAG) levels in the basal state are increased 
in the cerebellum of patients with FXS as well as in Fmr1 KO neurons. At synapses DAG 
molecules are produced through activation of postsynaptic receptors and DAG signaling 
triggers dendritic spine growth and stabilization (Kim et al., 2010); excessive DAG would predict 
the spine properties observed in the Fmr1 KO neurons (Tabet et al., 2016). Of interest, among 
the list of candidate FMRP targets there are regulators of the PI3K-based lipid-signaling 
pathway, mediators of lipid signaling or components that act as downstream effectors of 
proteins of the PI3K-mTOR-TSC cascade (Ascano et al., 2012; Darnell et al., 2011; Gross et 
al., 2015; Tabet et al., 2016). 
Another important signaling molecule downstream of the PI3K cascade is the glycogen 
synthase kinase 3 (GSK3), which is inhibited by AKT. This serine/threonine kinase regulates a 
variety of pathways involved in neurodevelopment, including neurogenesis, migration, axon 
growth and guidance, and synaptic plasticity (Santos et al., 2014). It is therefore not surprising 
that dysregulation of GSK3β contributes to a number of diseases such as mood disorders, 
schizophrenia and Alzheimer disease (King et al., 2014). Some evidence suggests that GSK3β 
activity is elevated in FXS mice (Min et al., 2009), and modulation of GSK3β activity has proven 
to be beneficial in FXS, as it reverses the dendritic spine deficits and the level of protein 
synthesis (Santos et al., 2014). Interestingly, GSK3β activity is down-modulated by lovastatin 
(Lin et al., 2016), a statin drug used for lowering cholesterol which has also an effect in inhibiting 
the Ras-ERK1/2 signaling pathway, exaggerated in FXS (Berry-Kravis et al., 2015; Caku et al., 
2014; Osterweil et al., 2010). This has set the basis for two pilot open-label trials of lovastatin 
in humans with FXS were performed and concluded (www.clincaltrials.gov). As lovastatin 
should actually lower cholesterol, low  and high density lipoprotein levels, possible problems 
associated with already excessively low lipid levels in individuals with FXS should be monitored 
(Berry-Kravis et al., 2015). Although these trials showed potential functional benefit, a placebo-
controlled trial is necessary to ascertain lovastatin efficacy in FXS. Clinical trials with statins 
have shown mixed results in improving cognition and behaviour in individuals with IDs and 
ASDs as Neurofibromatosis (NF1, van der Vaart et al., 2016), a monogenic form of 
syndromic autism, although the social and cognitive phenotype in animal models were rescued. 
Therefore, while the precise mechanisms underlying defective lipid signaling and IDs/ASDs 
remain to be identified, the availability of FDA-approved drugs targeting lipid signaling might 
provide a potential avenue for the treatment of IDs/ASDs-related synaptopathies. 
 
Metabotropic glutamate receptors 
The Gq-coupled, Group mGluRs are enriched at excitatory synapses throughout the 
brain, where they are strategically positioned to regulate glutamatergic signaling (Reiner and 
Levitz, 2018). They are crucial to synaptogenesis and formation of neural circuitry during brain 
  11 
development (Reiner and Levitz, 2018) and to mGluR-dependent long-term depression (LTD), 
an activity-dependent, NMDA-independent form of homosynaptic synaptic plasticity at Schaffer 
collateral to CA1 pyramidal synapses through adulthood (Oliet et al., 1997; Palmer et al., 1997). 
Importantly, modulation of mGluR5 corrects the bidirectional alteration of synaptic plasticity 
observed in Tsc2+/- and Fmr1 KO mice and the synaptic and cognitive defects were restored in 
the double mutant model (Auerbach et al., 2011). A recent finding shows that β-arrestin2 
provides an important link between mGluR5 and local translation in dendrites (Stoppel et al., 
2017). 
Expression of mGluR-LTD is mediated by persistent internalization of AMPA receptors 
and in adolescent mice requires de novo protein synthesis (Huber et al., 2002; Waung and 
Huber, 2009) with a noted requirement for the activity of the immediate early gene Arc encoding 
the Activity Regulated Cytoskeletal Protein that interacts with dynamin and endophilin to 
facilitate endocytosis of AMPARs (Chowdhury et al., 2006; Shepherd et al., 2006). Notably, Arc 
mRNA is an FMRP target at synapses (Zalfa et al., 2003) and dysregulation of Arc activity is 
implicated in aberrant synaptic plasticity and memory consolidation in Fmr1 KO mice (Park et 
al., 2008). Specifically, Fmr1 KO mice exhibit deficits in Hebbian forms of long term depression 
and potentiation, altered excitability, and delayed synaptic maturation (Contractor et al., 2015; 
Huber et al., 2002) . Fmr1 KO mice exhibit exaggerated mGluR-LTD at CA1 synapses leading 
to elevated protein synthesis, a hallmark of FXS (Huber et al., 2002). Genetic reduction of 
mGluR5 reverses many phenotypes in Fmr1 KO mice including exaggerated mGluR-LTD 
(Dolen et al., 2007). 
At synapses, association of mGluR5 with the interacting scaffolding protein Homer is 
compromised in Fmr1 KO mice, a feature that is rescued by genetic deletion of a short, 
dominant negative isoform of Homer, H1a (Guo et al., 2016; Ronesi et al., 2012). The 
mGluR1/5–Homer complex signals to the PI3 kinase enhancer PIKE, a target of FMRP (Darnell 
et al., 2011), which engages PI3K/AKT/mTOR signaling in response to synaptic stimulation 
(Figure 1, Gross et al., 2015). It is now well-established that PIKE is the upstream effector of 
overactivated mTOR signaling at hippocampal synapse, providing a functional link between 
loss of FMRP and overactivated mTOR signaling (and critical to mGluR-LTD, Gross et al., 2015; 
Sharma et al., 2010), FMRP itself has also been shown to be part of a complex with the 
regulatory subunit of the ubiquitin ligase Cdh1-anaphase-promoting complex (Cdh1-APC) that 
regulates mGluR-LTD in the brain (Huang et al., 2015).  
Given this evidence, a panel of mGluR antagonists has been tested not only in mouse 
models (MPEP, CTEP, Fenobam, AFQ056, STX107, RO491753), but also in individuals 
diagnosed with FXS, reviewed in (Bagni et al., 2012; Hagerman et al., 2017; Richter et al., 
2015). However, in clinical trials (www.clinicaltrials.gov), these drugs failed to ameliorate the 
most severe symptoms in humans. Data generated from several independent laboratories 
using biological models for the disease are in line with a dysregulated mGluR pathway. The 
possible discrepancy between the results generated in mice and the clinical trials in human 
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might suggest that patients' stratification together with learning based, outcome measures 
should developped (Berry-Kravis et al., 2018)  
In addition to Fragile X syndrome, dysregulation of mGluRs have been reported in other 
forms of intellectual disabilities and ASDs (Mahato et al., 2018). The Phelan-McDermid 
syndrome (PMS) is a neurodevelopmental disorder caused by genetic haploinsufficiency of the 
SHANK3 gene, which is a member of the Shank/ProSAP family of postsynaptic scaffolding 
proteins (Shank1, Shank2, and Shank3) that regulate multiprotein complex assembly in the 
postsynaptic density of excitatory synapses, and that has been identified in gene-linkage 
studies to be associated with autism (Monteiro and Feng, 2017). A mouse model of PMS, the 
Shank3 KO mouse, exhibits altered mGluR5-mediated signaling due to reduced association of 
mGluR5 with Homer1b/c and elevated levels of mGluR5 in PSDs, suggesting that mGluR5 
function may also be augmented (Wang et al., 2016). Pharmacological manipulation of mGluR5 
activity rescued impaired LTD at striatal synapses and elevated neuronal excitability and 
ameliorated ASD-relevant behaviors (Vicidomini et al., 2017; Wang et al., 2016). Of note, 
recently a missense variant in the SHANK3 gene revealed a novel function of Shank3, to recruit 
Abelson interactor 1 (ABI1) and the WAVE complex to the post-synaptic density, an event 
critical to synapse and dendritic spine development, a function which is independent of its 
binding to Homer (Wang et al., 2019). Mutations in the human SHANK2 gene (also known as 
ProSAP1) have been associated with ASDs and intellectual disabilities and SHANK2-mutant 
mice carrying a mutation identical to the ASD-associated microdeletion in the human SHANK2 
gene exhibit ASD-like behaviours. Those deficits were ameliorated by a positive allosteric 
modulator of mGluR5 (Won et al., 2012). Furthermore, overexpression of the scaffolding protein 
of Homer1a in the basal and lateral amygdala impaired auditory fear conditioning and induced 
autism-like reduced social interactions (Banerjee et al., 2016). These findings are significant in 
that mGluRs act through scaffolding proteins and downstream signaling to mediate the correct 
functioning of synapses. 
 
FMRP at synapses 
A recent study has shown that although FMRP is present throughout the brain, its 
expression varies markedly among different neuronal populations (Zorio et al., 2017). Within a 
given neuron, FMRP localizes to the soma, developing and mature axons, dendrites and the 
base of dendritic spines (Antar et al., 2004; Antar et al., 2006; Ferrari et al., 2007; Zimmer et 
al., 2017). Because neurons are so highly polarized, transport of mRNAs along the axon and 
dendrites to undergo local, on-site protein synthesis is key for maintaining its proper structural 
and functional polarity (Bramham, 2008; Cioni et al., 2018; Rangaraju et al., 2017; Tom Dieck 
et al., 2014). In these subcompartments, FMRP and its homologs, the Fragile X-related proteins 
(FXR1P and FXR2P) assemble with other RNA binding proteins and coding and noncoding 
RNAs to form large ribonucleoprotein particles or granules that tightly regulate mRNA transport, 
translation, stability, and degradation (Akins et al., 2012; Korsak et al., 2016; Pasciuto and 
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Bagni, 2014a, b). In axons and dendrites, Fragile X granules are transported along 
microtubules in a translationally-quiescent manner through interactions with kinesin, myosin 
and dynein motor proteins (Kanai et al., 2004). Different types of Fragile X granules are 
selectively expressed in specific neuronal circuits where they tightly regulate transport, 
localization, stability and translation of target RNAs (Akins et al., 2017; Chyung et al., 2018; 
Korsak et al., 2016). 
Several high-throughput approaches such as coimmunoprecipitation followed by 
microarray analysis (Brown et al., 2001), antibody-positioned-RNA amplification (APRA, 
Miyashiro et al., 2003) and crosslinking/immunoprecipitation with RNA sequencing (CLIP-Seq, 
Ascano et al., 2012; Darnell et al., 2011), led to the identification of hundreds of putative FMRP 
target mRNAs (>1,000 in brain and >6,000 in non-neuronal cells of which ~1000 were validated 
by RIP-Seq). The effect of FMRP binding to the majority of these target mRNAs still needs to 
be elucidated. As yet, only a few have been validated at the protein level, i.e., are known to 
have altered protein expression in the absence of FMRP, and even fewer have been shown to 
rescue functional Fmr1 KO phenotypes when their protein abundance is manipulated. 
Among the “core targets” of FMRP identified by these and other studies are a large 
number of mRNAs encoding pre- and postsynaptic proteins including NMDARs, mGluR5, PSD-
95, Shank1-3, Homer1, PIKE, neuroligins, neurexins, SNAP-25, AP-2, bassoon, synapsin and 
calcium channels (Pasciuto and Bagni, 2014b). Among the FMRP mRNA targets, several 
hundred (precisely 744) are bona fide axonally and/or dendritically localized mRNAs (Figure 
2). A substantial number (246) of these mRNAs are also associated with ASDs (Figure 2). A 
significant part of target mRNAs are transported and translated in an activity-dependent manner 
(Dictenberg et al., 2008; Ferrari et al., 2007). In dendrites and the postsynaptic compartment, 
FMRP regulates local ‘on site’ translation of Arc, α-CaMKII, PSD-95, Map1b, Fmr1 and GABAA 
receptors at dendritic spines (Antar et al., 2004; Dictenberg et al., 2008; Zalfa et al., 2007; Zalfa 
et al., 2003). FMRP also promotes stability of specific mRNAs, such as PSD-95 and GABA 
receptors, thereby preventing their decay in specific brain regions and in specific 
subcompartments within a given neuron (Braat and Kooy, 2015; Miyashiro et al., 2003; Zalfa 
et al., 2007; Zhang et al., 2007).  
It is now well accepted that maintaining a fine balance between the synthesis and 
degradation of RNAs and correct number of mRNAs and RNA-binding proteins is crucial to the 
proper structure and function of the synapse and, when dysregulated, result in synaptopathies 
(Grant, 2012) such as FXS and other ASDs (Bagni et al., 2012; Gandal et al., 2018; Klein et 
al., 2016; Parras et al., 2018). In normal cells, FMRP tightly regulates mRNA stability, transport 
and translation. Some of these posttranscriptional processes are also affected in other ASDs. 
FMRP appears to fine-tune the proteome to match the changing needs of the cell/synapse. 
Neuronal gene expression is controlled with exquisite spatial and temporal resolution, including 
activity-dependent transcription in the nucleus and local translation at the synapse. Targets of 
FMRP include many mRNAs that encode synaptic and other plasticity-related proteins, which, 
  14 
when dysregulated, result in the cognitive impairment and other features in common between 
FXS and ASDs (Figure 1). Typical of RNA-binding proteins, the targeting specificity of FMRP 
seems to be determined by a cooperative interplay among several RNA-binding motifs within 
FMRP itself and/or its binding partners (Achsel and Bagni, 2016). 
An additional source of complexity and heterogeneity comes from chemical 
modification, e.g., methylation and pseudouridylation, of synaptic mRNA and RNA. While 
enzyme-mediated mRNA modifications are known to regulate cellular mRNA turnover, the role 
of these modifications in regulating synaptic RNA started to be explored only recently. It was 
shown that the brain non-coding RNA BC1 is differentially 2’-O-methylated in the cell body and 
at synapses and the change in modification affects its interaction with FMRP (Figure 3) in the 
different subcellular compartments (Lacoux et al., 2012). Methylation of adenosine in RNA to 
N6-methyladenosine (m6A), the most common mRNA modification present in about one quarter 
of all RNAs (Arguello et al., 2018), appears to be relevant to synaptic pathologies. Recently the 
synaptic m6A epitranscriptome was mapped and shown to be functionally enriched in pathways 
implicated in neurodevelopmental and neuropsychiatric diseases (Merkurjev et al., 2018).  
Additional evidence was generated underlining a key role of FMRP in recognition and 
regulation of modified RNAs. High methylation levels of FMRP target mRNAs suggest that m6A 
methylation is likely to be used for selective recognition of target mRNAs by FMRP at the 
synapse (Chang et al., 2017). More specifically, FMRP was bound to the m6A sites of its mRNA 
targets and interacts with m6A reader YTHDF2 in an RNA-independent manner. FMRP 
maintains the stability of its mRNA targets, while YTHDF2 alone promotes the degradation of 
these mRNAs. These data together suggest that FMRP regulates the stability of its m6A-marked 
mRNA targets through its interaction with YTHDF2 (Zhang et al., 2018). Furthermore, 
transcriptomic analysis of post-mortem brains of patients with ASDs and FXS revealed 
hypoediting in the brains of both, which was shared across brain regions and involved many 
synaptic genes. These findings are mechanistically explained by the interaction of the Fragile 
X proteins: FMRP and FXR1P interact with RNA-editing enzymes (ADAR proteins) and 
modulate A-to-I editing (Arguello et al., 2018; Tran et al., 2019). 
 
FMRP lost in synaptic translation 
After more than 18 years of studies addressing the properties of neurons lacking 
FMRP, excessive translation is posited to be a major contributor to the synaptic and cognitive 
deficits in Fragile X syndrome (Bagni et al., 2012; Banerjee et al., 2018; Darnell and Klann, 
2013; Richter et al., 2015). Of note, enhanced mRNA translation was first reported in 
lymphoblastoid cells derived from humans with FXS (Brown et al., 2001) and at synapses of 
Fragile X mice (Dolen et al., 2007; Greenough et al., 2001; Zalfa et al., 2003). FMRP represses 
protein synthesis by different mechanisms regulating initiation (Figure 1) and elongation of 
mRNA translation (Bagni et al., 2012; Richter et al., 2015; Zukin et al., 2009).  
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In brain and at synapses several converging lines of evidence suggest that translational 
repression occurs mainly at the level of initiation (Sossin and Costa-Mattioli, 2018) regulating 
the assembly of the pre-initiation complex containing the small ribosomal subunits. The 
efficiency of mRNA translation is regulated through phosphorylation of translation initiation 
factors such as eIF4E or the eIF4E-binding proteins (4E-BPs). Phosphorylation of eukaryotic 
initiation factors eIF4E and/or 4EBPs by mTORC1 or MNK1 releases the brake imposed on 
translation (Bramham et al., 2016), enabling assembly of eIF4E with eIF4G to form the initiation 
complex. Mice carrying a genetic mutation in eIF4E-BP2 exhibit increased ratio of E/I, 
increased translation of neuroligins (NLGNs), as well as autistic behaviors. Modulation of Nlgn1 
corrected the defects and worsened autistic phenotypes (Gkogkas et al., 2013; Wang and 
Doering, 2013). Of note, NLGNs promote synaptic transmission (Varoqueaux et al., 2006) and 
are regulated by FMRP at synapses (Chmielewska et al., 2018; Darnell et al., 2011; Pasciuto 
and Bagni, 2014b). 
Hypersensitivity to mGluR5 and ERK signaling also contributes to excessive protein 
synthesis in the hippocampus of Fmr1 KO mice. At synapses, the MAPK pathway regulates 
local protein synthesis by phosphorylation of TSC2, thus modulating mTOR activity (Lipton and 
Sahin, 2014). Moreover, phosphorylation of ribosomal protein S6, primarily a downstream 
target and effector of mTOR, is also elevated and phosphorylated by ERK via the alternative 
S6 kinase RSK. Finally, MAPK phosphorylates and activates MAP kinase- serine/threonine-
protein kinases (MNKs); phosphorylation and activation of eIF4E by MNKs promotes initiates 
elongation and translation (Panja et al., 2014). 
While the above-mentioned mechanisms regulate general mRNA translation, specific 
mRNA translation is orchestrated by FMRP via multiple mechanisms (Figures 1 and 3). FMRP 
regulates translational initiation by binding cytoplasmic FMR1-interacting protein 1 (CYFIP1), 
which subsequently sequesters and inhibits eukaryotic initiation factor (Napoli et al., 2008). In 
this complex, CYFIP1 acts as a non-canonical eIF4E-binding protein (4E-BP), which represses 
translation of target mRNAs by occluding the eIF4G binding site on eIF4E (Napoli et al., 2008). 
The CYFIP1-FMRP complex represses translation of dendritically localized FMRP target 
mRNAs such as: Map1b, αCaMKII, Arc and APP (Napoli et al., 2008). Under basal conditions, 
~30% of neuronal CYFIP1 is contained within the CYFIP1-FMRP-eIF4E complex, and ~70% is 
contained in the WAVE regulatory complex, consistent with the concept that the same CYFIP1 
molecule cannot be part of both complexes at the same time (De Rubeis et al., 2013). 
Remarkably, synaptic activity in the form of either brain-derived neurotrophic factor (BDNF) or 
mGluR signaling triggers a conformational change in CYFIP1, from globular (Di Marino et al., 
2015) to planar (Chen et al., 2010b). This conformational change is driven in part by the 
interaction of CYFIP1 with the small Rho GTPase Ras-related C3 botulinum toxin substrate 1 
(Rac1) and releases eIF4E from CYFIP1, enabling assembly of eIF4E with eIF4G to form the 
first translation initiation complex, which can then proceed to position ribosomes on the mRNA 
(De Rubeis et al., 2013; Napoli et al., 2008). CYFIP1 can be phosphorylated by MNK, releasing 
translational inhibition and promoting many protein-synthesis forms of synaptic plasticity (Panja 
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et al., 2014). More specifically, it was shown that at synapses of the dentate gyrus early in 
translation, MNK triggers release of the CYFIP1-FMRP inhibitory repressor complex from the 
mRNA. During late-stage translation, MNK regulates the canonical translational repressor 4E-
BP2 in a synapse compartment-specific manner. This late stage is coupled to MNK-dependent 
enhanced dendritic mRNA translation (Panja et al., 2014). Therefore, the FMRP-CYFIP1-eIF4E 
inhibitory complex ensures an appropriate rate of local protein synthesis in response to synaptic 
activity, which is crucial for triggering long-term synaptic plasticity at glutamatergic synapses 
(Figure 1). 
Synaptic plasticity requires actin remodeling and protein synthesis; thus, a balance 
between these two processes is crucial for brain functioning (De Rubeis et al., 2013). CYFIP1 
is also a component of the WAVE regulatory complex (a heteropentamer formed by 
WAVE1/2/3, CYFIP1/2, ABI1/2, NCKAP1 and HPSC300), which promotes actin remodeling 
through its interaction with the Arp2/3 complex (Chen et al., 2010b; Eden et al., 2002). CYFIP1 
shuttles between the FMRP-eIF4E complex and the Rac1-WAVE regulatory complex, thereby 
linking protein translation to spine dynamics and actin remodeling (De Rubeis et al., 2013). 
Moreover, treatment of mice with 4EGI-1, an inhibitor of the eIF4E-eIF4G translation initiation 
complex creates free eIF4E that competes with Rac1 to bind CYFIP1, thus restoring the 
balance between these signalling pathways ultimately correcting deficits in hippocampal-based 
memory and spine morphology (Santini et al., 2017). These findings are consistent with the 
concept that dysregulation of protein translation and actin dynamics are critical to the 
pathophysiology of Fragile X.  
FMRP can repress mRNA translation at the level of initiation through the action of 
microRNAs such as miR-125a on PSD-95 mRNA or miR-196a on HOXB8 mRNA (Li et al., 
2014; Muddashetty et al., 2011) or micro RNA 125b on NR2A mRNA (Edbauer et al., 2010, 
Figure 3). In this context the modulation of the translational inhibition occurs through FMRP 
phosphorylation. Neuronal activity and/or activation of mGluR5 promotes protein phosphatase 
2A (PP2A)-dependent dephosphorylation of FMRP, which induces release of the RISC and 
stimulation of active translation. Activation of mGluRs also promotes ubiquitination of FMRP, 
which primes FMRP for ubiquitin-based, proteasomal degradation locally (Hou et al., 2006; 
Nalavadi et al., 2012), likewise releasing FMRP from the complex. In addition to ubiquitinylation, 
FMRP can be sumoylated with similar effects: FMRP is rapidly sumoylated in response to 
neuronal activity and by activation of mGluR5 (Khayachi et al., 2018). The increase in 
sumoylation promotes homomerization and release of FMRP from dendritic RNA granules, 
enabling local protein synthesis, which promotes spine elimination and maturation (Khayachi 
et al., 2018). Additional evidence towards a mechanism of FMRP-mediated translational 
regulation at the level of initiation came from a study showing that the antidiabetic drug 
metformin rescues some FXS phenotypes in mice, which coincides with selective normalization 
of ERK signaling and eIF4E phosphorylation (Figure 1, Gantois et al., 2017). Of note, metformin 
is a drug known to activate autophagy that is also impaired in Fragile X (section below and 
References), making it a candidate for drug redirection (Tranfaglia et al., 2018). 
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The role of FMRP, however, is not limited to inhibition of translation initiation. FMRP 
can also regulate mRNA translation during elongation, via stalled polyribosomes (Darnell et al., 
2011), while another study identified FMRP as translational activator for specific mRNAs (Tabet 
et al., 2016). In the future it will be interesting to address if the identity of the target mRNA 
determines the regulatory mechanism (Achsel and Bagni, 2016), or if FMRP can switch its 
mechanistic role depending on the developmental or physiological state of the cell/subcellular 
compartment. 
FMRP regulates the expression and activity of a substantial number of voltage-gated 
ion channels (Contractor et al., 2015; Ferron, 2016; Richter et al., 2015). For example, FMRP 
controls the translation of Kv4.2, Kv3.1, and HCN1 mRNAs encoding K+ channels that control 
neuronal excitability (Brown et al., 2001; Darnell et al., 2011; Miyashiro et al., 2003). In addition 
to these translation-dependent mechanisms by which FMRP controls channel abundance, 
FMRP acts via non-canonical (translation-independent) mechanisms to regulate activity and 
stability of other voltage-gated channels by direct protein-protein interactions, which in turn, 
alters cellular excitability. In particular, the N-terminal region of FMRP contains two Tudor motifs 
that typically recognize methylated amino acids (Maurer-Stroh et al., 2003) in proteins or FMRP 
RNA binding partners (Lacoux et al., 2012). FMRP binds and modulates activity/properties of 
the Slack and BK potassium channels through this domain, while it interacts with calcium 
channels via its carboxy-terminus. The interaction of FMRP with Slack opens the channel 
(Brown et al., 2010) and in the case of BK channels, which are also expressed presynaptically, 
causes broadening of the action potential (Deng and Klyachko, 2016). The interaction of FMRP 
with calcium channels targets the channels for ubiquitin-based, proteasomal degradation and 
modulates N-type calcium channel density and synaptic vesicular release (Ferron et al., 2014). 
 
Synapse elimination and spine pruning 
Synaptic activity influences the number and strength of synapses that form between 
neurons. During early brain development, synapse formation exceeds elimination, resulting in 
an excess of immature excitatory synapses. Later, synapse destabilization and elimination 
reduces the number of synapses, thus refining neural circuits that underlie behavior and 
cognition (Rakic et al., 1986). Synaptogenesis and synapse elimination follows different time 
lines in anatomically and functionally distinct regions. Excess synapses are eliminated or 
pruned in a manner that depends on sensory experience and synaptic activity (Berry and 
Nedivi, 2017; Chen and Sabatini, 2012; Mostany et al., 2013; Sudhof, 2018).  
An important clue as to the mechanism/s by which synapse elimination is regulated 
during brain development came from studies on the myocyte enhancer factor (MEF) 2 family 
of transcription factors. MEF2 members are highly expressed in brain and tightly regulated in 
response to Ca2+ signaling, and promote expression of a set of genes that restrict the number 
of synaptic connections in between hippocampal neurons. Three autism genes, namely Fmr1, 
the ubiquitin E3 ligase murine double minute-2 (Mdm2), and Protocadherin-10 (Pcdh10), a 
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member of the cadherin superfamily of Ca2+-dependent cell adhesion proteins, are required for 
MEF2-dependent synapse elimination and act downstream of MEF2 (Pfeiffer et al., 2010; Tsai 
et al., 2012). Upon activation of MEF2, Mdm2 ubiquitinates the synaptic scaffolding protein 
PSD-95, enabling recognition by PCDH10, which targets PSD-95 to the proteasome for 
degradation and promotes synapse elimination. FMRP controls expression of eukaryotic 
elongation factor 1a (EF1a), which in turn prevents MEF2-dependent PSD-95 ubiquitination 
and synapse elimination (Tsai et al., 2017). Moreover, PCDH10 was discovered to serve as a 
ligand for the WAVE regulatory complex implicated in control of actin cytoskeletal dynamics, 
linking PCDH10 to cofilin signaling and structural remodeling of spines (Chen et al., 2014). Of 
note, human genetic studies have implicated PCDH10 in ASDs (Morrow et al., 2008) and the 
MEF2 family member MEF2C as a convergence point for multiple signaling pathways involved 
in the pathogenesis of ASDs (Gilissen et al., 2014; Tu et al., 2017). These findings reveal novel 
roles for multiple autism-linked genes in activity-dependent synapse elimination. 
 
Actin dynamics at FXS and ASDs synapses 
Synaptic strength is largely influenced by changes in synaptic structure which rely on 
regulation of receptor signalling, local protein synthesis and structural remodelling of the 
cytoskeleton (Jedrzejewska-Szmek and Blackwell, 2019; Nakahata and Yasuda, 2018). A 
major player is the actin cytoskeleton, actin being the most abundant cytoskeletal protein in 
spines (Cingolani and Goda, 2008; Hotulainen and Hoogenraad, 2010; Lamprecht, 2014). One 
of the key regulators of actin dynamics, and hence synaptic plasticity, is the small Rho GTPase 
‘Ras-related C3 botulinum toxin substrate 1’ (Rac1, Figure 1). First, Rac1-GTP binds to 
CYFIP1, activating WRC-mediated actin polymerization while at the same time disinhibiting 
local protein synthesis (see above). Second, Rac1-GTP activates the p21-activated kinases 
(PAK1-3), which activate LimK. Activated LimK1, in turn, phosphorylates and inactivates its 
target cofilin. Cofilin is a depolymerizing factor and major determinant of dendritic spine structure 
that severs the actin filament (F-actin) at its pointed ends (Bamburg and Bernstein, 2010; 
Mizuno, 2013) to regulate spine morphology, spine motility and synaptic plasticity (Bosch and 
Hayashi, 2012; Hotulainen and Hoogenraad, 2010; Lin and Webb, 2009; Pontrello and Ethell, 
2009). Growing evidence from studies involving non-neuronal cells indicates that mTORC2 
regulates the actin cytoskeleton through Rac1 (Hernandez-Negrete et al., 2007; Huang et al., 
2013). In addition, cofilin is a direct target of mTORC2 (Tejada-Simon, 2015). 
Dysregulation of the synaptic cytoskeleton is a common theme in the pathogenesis of 
neurodevelopmental disorders and FXS (Bai et al., 2015; Bourgeron, 2015; De Rubeis et al., 
2014; Joensuu et al., 2018; Penzes and Cahill, 2012; Penzes et al., 2011; Pyronneau et al., 
2017). Considerable evidence indicates that Rac1 signaling is a point of convergence in 
ASD/IDs. Mutations in Rac1 have been detected in ASD/IDs and disruption of Rac1 signalling 
contributes to ASD-like behaviours in animal models (De Rubeis et al., 2013; Dolan et al., 2013; 
Tian et al., 2018; Zeidan-Chulia et al., 2013). Aberrant Rac1 activation leads to either 
  19 
abnormally weak or strong glutamatergic synapses (Sadybekov et al., 2017). Of note, Rac1 
levels are increased in FXS patients (Fatemi et al., 2013) and baseline activation of the Rac1 
pathway is upregulated in the Fmr1 KO mouse model (Santini et al., 2017). Loss of FMRP leads 
to increased Rac1 signaling, which is mediated by increased interaction between Rac1 and the 
scaffolding protein CYFIP1. In Fmr1 KO brains, an increased abundance of the initiation eIF4E-
eIF4G and CYFIP1-Rac1 complexes is observed, thereby blunting synaptic plasticity and 
learning. Treatment of FXS mice with 4EGI-1, which inhibits interactions between eIF4E and 
eIF4G, restored the equilibrium between the CYFIP1-Rac1 and protein synthesis and thereby 
reversed defects in hippocampus-dependent memory and spine morphology (Santini et al., 
2017). 
Formation and maintenance of dendritic spines is maintained through PAK1 and 
several PAK isoforms have been implicated in IDs (Asrar et al., 2009; Causeret et al., 2009; de 
la Torre-Ubieta et al., 2010). Abundance and activity of Rac1 and PAK1 are elevated in the 
somatosensory cortex of Fragile X mice (Bongmba et al., 2011; Castets et al., 2005; Chen et 
al., 2010a; de Diego-Otero et al., 2009; Dolan et al., 2013) and inhibition of PAK1 rescues, in 
part, the increased density and length of dendritic spines in Fmr1 knockout mice (Dolan et al., 
2013; Hayashi et al., 2007; Pyronneau et al., 2017). Pak2 haplo-insufficiency results in 
markedly decreased density of synapses, impaired long-term potentiation, and autism-relevant 
behaviours in mice due to reduced activity of the key actin regulators LIMK kinase 
(LIMK)1/cofilin (Wang et al., 2018). PAK1 and PAK3 are also involved in spine morphogenesis 
and neural plasticity (Boda et al., 2006). Moreover, PAK3 is associated with non-syndromic X-
linked mental retardation (Allen et al., 1998; Bienvenu et al., 2000). PAKs are also the molecular 
targets of SHANK3 linked to autism-related behaviors (Duffney et al., 2015). 
 There is considerable evidence that implicates dysregulation of LIMK/cofilin signaling in 
the aberrant spine morphology associated with Fragile X. Cofilin is dysregulated in the 
somatosensory cortex of young Fmr1 KO mice and causally related to spine abnormalities 
(Pyronneau et al., 2017). Constitutively active (non-phosphorylatable) cofilinS3A corrects 
aberrant spine morphology and density in the somatosensory cortex, indicating a causal 
relation between elevated cofilin phosphorylation and an overabundance of immature spines. 
LIMK-cofilin signaling can also be stimulated by bone morphogenetic protein type II receptor 
(BMPR2). In humans, the full-length isoform of bone morphogenetic protein type II receptor 
(BMPR2) is elevated and activates LIMK1 (Kashima et al., 2016). Heterozygosity for BMPR2 
or pharmacological inhibition of LIMK1 reduced the density of immature spines and restored 
synaptic function in Fragile X mice. It would be interesting to explore whether BMPR2 is the 
link between FMRP loss and Rac1 activation or if these represent independent pathways which 
converge on LIMK1. 
 
mTOR and Autophagy 
  20 
 The correct number of proteins is maintained by a fine balance between protein 
synthesis and protein degradation. Elevated levels of synaptic proteins can arise as a 
consequence of elevated translation and/or impaired protein degradation. Autophagy is a 
process of programmed degradation and recycling of cellular components via the lysosomal 
pathway that is increased during periods of cellular stress (Harris and Rubinsztein, 2011; 
Mizushima et al., 2008; Nixon, 2013; Wong and Cuervo, 2010). In neurons, mTORC1 is 
strategically positioned at pre- and postsynaptic sites where it serves as a brake on autophagy. 
Under nutrient-rich conditions, mTOR phosphorylates Unc-51-like autophagy-activating kinase 
1 (ULK-1) at S757 (Figure 4), a target of mTORC1 and well-established anti-autophagy site 
(Jung et al., 2009). This, in turn, sequesters ULK-1 away from AMP kinase (AMPK) and halts 
the initiation of autophagy. By contrast, under conditions of starvation, AMPK phosphorylates 
and activates ULK-1 at S317. Upon activation, ULK-1 promotes phosphorylation and activation 
of Beclin-1 at S14, a critical step in the ‘nucleation phase’ of autophagy (Russell et al., 2013). 
Beclin-1 promotes lipidation of LC3-I to generate its lipidated form LC3-II, enabling elongation 
of the limiting membrane and formation of autophagosomes (Rubinsztein et al., 2012). Upon 
lipidation, LC3-II localizes to the phagophore membrane, enabling elongation of the limiting 
membrane and formation of mature LC3-II (+) autophagosomes, which engulf the cargo (Harris 
and Rubinsztein, 2011; Mizushima et al., 2008; Nixon, 2013). Autophagosomes act via cargo 
adaptor proteins such as p62 to deliver ubiquitinated proteins, protein aggregates and 
organelles to lysosomes for degradation. 
In neurons, autophagy plays an important role in protein homeostasis and is a key 
regulator of structural remodeling, synaptic plasticity, and memory formation (Nixon, 2013; 
Shehata et al., 2012). Molecules such as the cargo adaptor protein p62 recognize and bind 
ubiquitinated proteins and target them for degradation via the lysosomal/autophagy pathway. 
A possible scenario is that in hippocampal neurons from Fragile X mice, overactivated mTOR 
leads to reduced autophagy and a build-up of a select group of synaptic proteins. It was recently 
observed that in neurons, inhibition of either ubiquitin-based, proteasomal degradation or the 
autophagy/lysosomal pathway lead to the buildup of synaptic proteins such as Arc and PSD-
95, consistent with the concept that both pathways are involved in degradation of these and 
potentially other synaptic proteins under physiological conditions (Yan et al., 2018). Neurons 
from Fmr1 KO mice exhibited a buildup of ubiquitinated protein aggregates, which colocalized 
with p62, consistent with the concept that autophagy is impaired in neurons lacking FMRP (Yan 
et al., 2018). In addition, overactivated mTOR signaling suppresses autophagy in the brains of 
Tsc1+/− and Tsc2+/− mice during postnatal development, and reduced autophagy is causally 
linked to impaired pruning of spines in cortical layer V pyramidal neurons. The autism-relevant 
behaviors in the Tsc mutant mice suggest that impaired autophagy and its link to impaired spine 
pruning is likely to be more widespread in at least a subset of ASDs (Tang et al., 2014). 
 
Conclusions and future perspectives 
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In this article, we have reviewed dysregulated molecular signaling cascades, receptors, 
synaptic function and plasticity and spine architecture that underlie the behavioural and 
cognitive deficits associated with Fragile X syndrome and other forms of syndromic ASDs. We 
have argued for a partial overlap between the pathogenetic mechanisms that lead to FXS and 
ASDs. Therefore, advances in our understanding of FXS may also help to inform studies on 
other ASDs. More importantly, personalized strategies to treat the social endophenotypes of 
FXS may also be beneficial for other forms of syndromic – and perhaps even idiopathic – ASD. 
Several forms of syndromic autism and intellectual disabilities are associated with 
mutations in genes that regulate protein synthesis and affect structure, transmission and 
plasticity of synapses (Zoghbi and Bear, 2012). Failure to maintain the precise number of 
mRNA molecules and RNA binding protein levels are crucial entry points of synaptopathies 
(Grant, 2012). Neuronal gene expression undergoes changes at very fine spatial and temporal 
scales, including changes induced by activity-dependent transcription in the nucleus and local 
translation at the synapse. A fascinating frontier for the study of local translation is the question 
of heterogeneity in the basic translation machinery at synapses and during development. It was 
recently shown that the ribosome has a very heterogeneous composition, allowing for selective 
translation of transcripts responsible for different cellular functions such as metabolism, cell 
cycle, and development (Shi et al., 2017). If and in which context specialized ribosomes are 
found at axons and dendrites is the new frontier to brain development in physiological and 
pathological conditions such as FXS and ASD.  
FMRP appears to fine-tune the proteome to match changing needs of the cell/synapse. 
A multitude of mRNAs that are targeted by FMRP belong to various biological pathways that 
are affected in ASDs (Figure 1). The targeting specificity of FMRP seems to be determined by 
a cooperative interplay of several RNA-binding activities (Achsel and Bagni, 2016), e.g., FMRP 
itself, miRNAs, and/or BC1 RNA. The full repertoire of FMRP-containing mRNP complexes is, 
however, far from elucidated, and new experimental and bioinformatic paradigms are needed 
to gain a thorough understanding of the molecular functions of FMRP. The identification of 
FMRP synaptic partners - RNA and proteins - their cell specificity and expression during a 
developmental trajectory will shed light into such a complex neurodevelopmental disorder. The 
multitude of FMRP direct and indirect effects as well the multitude of genes implicated in ASDs 
(www.SFARI.org) are matched by a consistent heterogeneity in the phenotypes of FXS and 
ASD patients, indicating that the individual genetic and/or epigenetic background determines 
which FMRP and or ASD gene mechanism becomes prevalent in the expression of the disease 
phenotype. This calls for disease models that take individual patients’ backgrounds into 
account. The heterogeneity of FXS and ASDs in humans that underlies the individual variability 
may explain, at least in part, the lack of success of clinical trials aiming solely at decreasing 
protein synthesis. A recent study highlighted a large variability in the levels of protein synthesis 
in fibroblasts among patients diagnosed with FXS (Jacquemont et al., 2018). These findings 
suggest that future clinical trials should aim at stratifying the FXS population, define reliable 
endophenotypes, and then target them in personalized treatment strategies. For such 
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stratification, as well as for earlier identification of ASDs, it is first necessary to identify suitable 
biomarkers, which have to be selected from the existing lists of genetic and molecular 
biomarkers, as well as from neuroimaging and cognitive studies.  
Although research involving the mouse model has informed our understanding of the 
pathophysiology of Fragile X including deficits in signaling, synaptic plasticity and behavior, and 
several clinical trials have been implemented based on data from the mouse, there is to date 
no effective treatment for the cognitive and social interaction deficits observed in humans with 
FXS. Other disease models, such as the Fmr1 KO and other ASD rats, have been developed 
to better mimic the human phenotype (Berzhanskaya et al., 2017; Hamilton et al., 2014; 
Harony-Nicolas et al., 2017; Saxena et al., 2018). A recent study involving iPS cells derived 
from patients with Fragile X demonstrated rescue of the synaptic deficits associated with Fragile 
X by CRISPR-dependent DNA methylation editing (Liu et al., 2018). This and related studies 
have propelled a paradigm shift from studies involving the Fragile X and ASD rodent models to 
those involving patient-derived iPS cells (Bhattacharyya and Zhao, 2016; Linda et al., 2018; 
Sacco et al., 2018). Advantages of iPS cells are several-fold. In particular, iPS cells are derived 
from fibroblast cells of individual patients and therefore reflect the genomic heterogeneity found 
in the patient population. iPSC-derived neurons from individuals with FXS have been generated 
and used to develop a strategy to reestablish FMRP expression by promotor demethylation 
(Bhattacharyya and Zhao, 2016; Liu et al., 2018). Similar approaches should be used to screen 
for compounds that reset translational homeostasis, reduce hyperexcitability, and/or accelerate 
maturation in iPSC-derived neurons from individuals with ASDs and/or FXS. Yet, iPS cells, or 
even neurons induced from iPS cells, are not a suitable model to study human behavior. 
We envision that mechanistic research using animal models and patient-derived stem 
cells will help researchers to understand the complex etiology of neurodevelopmental disorders 
such as FXS and ASDs, which will hopefully lead to more effective therapeutical strategies 
including personalized pharmacogenomics targets.  
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Figure legends 
 
Figure 1. Simplified model of the mTOR – ERK1/2 - WAVE signaling pathways at 
synapses. mGluR receptors mediates activation of PI3K via scaffolding proteins such as PIKE 
and HOMER, leading to the activation of AKT and inhibition of TSC1-TSC2 complex. TSC2 
inhibition of RHEB activates mTORC1, resulting in FMRP phosphorylation by S6 Kinase. The 
phosphorylation status affects its RNA-binding properties as well as its translational regulation. 
FMRP interacts with the initiation factor eIF4E and regulates translational through the specific 
eIF4E-binding protein CYFIP1. In Fmr1 KO mice and FXS individuals PI3K is upregulated, 
leading to an increased mTOR phosphorylation, culminating in an increased protein synthesis. 
mTORC2 has a central role in actin remodeling through its actions on RAC1 and LIMK 
phosphorylation on the actin-depolymerizing factor cofilin (CFL). Proteins encoded by genes 
associated to ASDs (SFARI database, http://gene.sfari.org) are colored in orange. 
 
Figure 2. Shared genes among FMRP targets, axonal/dendritic transcriptome and ASDs. 
Among the 1842 identifies putative FMRP targets, 271 are in common with ASD genes, and 
859 are in common with the axonal/dendritic transcriptome. Moreover, 146 genes are shared 
with all three classes. 1842 FMRP targets are based on the work from (Ascano et al., 2012; 
Brown et al., 2001; Chen et al., 2003; Darnell et al., 2011; Miyashiro et al., 2003) and the list 
by (Ascano et al., 2012) filtered for brain expression. 1065 ASD genes are from the SFARI 
database, AutDB database (Pereanu et al., 2018) and (Mahfouz et al., 2015). 5028 genes from 
the axonal and dendritic localized transcriptome are based on the work by (Cajigas et al., 2012) 
and (Gumy et al., 2011). 
 
Figure 3. FMRP differently recognizes neuronal mRNAs. Four principal mechanisms of 
FMRP mRNA target recognition. (A) FMRP can recognize G-quartet structure and G-rich 
regions of the target mRNA (B) FMRP can binds specific RNA recognition elements (RREs) 
such as ACUK and WGGA (Ascano et al., 2012) (C). FMRP can bind indirectly the mRNA 
targets through either the small non-coding RNA brain cytoplasmic RNA 1 (BC1) or microRNAs 
(miRNAs) (D). Modified from (Bagni and Greenough, 2005). 
 
Figure 4. A schematic of the process and main regulatory machinery of the autophagy. 
The metabolic sensors mTOR and AMPK are the main regulators of autophagy activation. 
mTORC1 phosphorylates ULK-1, inhibiting autophagy. In condition of nutrient depletion and 
cellular stress AMPK phosphorylates and activates ULK-1 promoting phosphorylation and 
activation of Beclin-1, a critical step in the nucleation phase of autophagy. Cytoplasmic material 
is engulfed by double membranes forming a cup-shaped structure called phagophore. Beclin-
1 promotes LC3-I lipidation to generate its lipidated form LC3-II, enabling elongation of the 
  24 
limiting membrane of the phagophore and formation of autophagosomes. Autophagosomes 
require protein adaptors such as p62 to deliver proteins and organelles to lysosomes for 
degradation in the autolysosome. FMRP inhibits mTORC1 and Fmr1 KO mice show an over-
activation of mTORC1 with consequent hyperphosphorylation of ULK1/2 and downregulation 
of autophagy (Yan et al., 2018).  
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